AMSBIO introduces highly efficient substrate for culturing ES/iPS cells
![](/46/pdcnewsitem/04/97/09/amsbiopr209-image.jpg)
iMatrix recombinant Laminin-511 E8 protein fragments permit ES/iPS cells to be maintained in xeno-free, feeder-free culture conditions enabling easy application in medical trials.
iMatrix recombinant Laminin-511 E8 fragments from AMSBIO is an innovative cell culture matrix compatible with a wide variety of cell types, and exceptionally well suited for pluripotent stem cells.
Laminin-511 is a major component of the basement membrane, which is expressed in early development of the embryo and can be used as a matrix for pluripotent (ES/iPS) stem cells, as it binds to integrin on cell surfaces. However, Laminin-511 is a large protein (800kDa) composed of three chains (alpha, beta and gamma) forming a supramolecular aggregate, making it difficult to produce recombinantly. In order to overcome this challenge, Laminin-511 proteins were fragmented to find the smallest integrin-binding component and hES cells were found to adhere more strongly to the E8 fragment than to the full-length protein.
iMatrix recombinant Laminin-511 E8 protein fragments from AMSBIO permit ES/iPS cells to be maintained in xeno-free, feeder-free culture conditions enabling easy application in medical trials. In an independent study iMatrix and other cell culture substrates were compared for their strength in adhering to hES cells. The study showed that the iMatrix adhered to cells more strongly than to Matrigel or full-length Laminin and Vitronectin cell culture matrices.
AMSBIO iMatrix recombinant Laminin-511 E8 protein fragments also demonstrates highly efficient bulk cell proliferation. Using iMatrix it is possible to achieve a 1,000-fold increase in numbers of ES/iPS cells after one month culture, this is 200 times more than using the conventional colony method.
In addition, using the iMatrix recombinant Laminin-511 E8 fragment as a cell culture matrix enables you to culture single ES/iPS cells almost immediately, thereby reducing the time required to optimize culture methods and drastically enhancing efficiency of cell cultures.
AMSBIO's recombinant iMatrix Laminin-511 E8 protein fragments can be used pre-mixed as well as in conventional pre-coating techniques. Pre-mixing saves time and money for as less material is required and there is no need to pre-coat dishes.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance